Market Currents
Roth Capital steps to the sidelines on Peregrine Pharmaceuticals (PPHM -79%), downgrading it to...
-
Monday, September 24, 2012, 3:49 PM ETRoth Capital steps to the sidelines on Peregrine Pharmaceuticals (PPHM -79%), downgrading it to Neutral and removing it from its Focus List due to the uncertainty over the discrepancies in its Phase II study of bavituximab. The firm also skewered its price target on the shares, slashing it to $0.70 from $9.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
This news story has 8 comments:
So worthless.
They pumped and then dumped the stock and are simply waiting to pick up the stock at 75% discount form just one trading day ago. The stock market is rigged and only the big boys that borrow money at 0% from the corrupt FED can afford to gamble on the stock market. IN a month or so PPHM will be on the rise once again. I lost 6K before I woke up this morning and before the market even opened. I'll hang on to my shares and just wait until they study the "discrepancies" and issue a Press release saying it was not as bad as they figured. There is simply way too hundreds of million bet on this lung cancer drug for it to go belly up. Then again if I am wrong I'm out of most of my investment in it anyway. The only way to go is up.
Maybe now they wlll have another 1 for 10 reverse split. URGGHHH!
I see this stock going to $.001, but I am usually wrong about this so called compnay